LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

Начало・Списък с акции・Beam Therapeutics Inc

Beam Therapeutics Inc

Затворен

СекторЗдравеопазване

27.35 -1.94

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

26.09

Максимум

28.06

Ключови измерители
By Trading Economics
Приходи	-10M -113M
Продажби	1.2M 9.7M
Марж на печалбата	-1,162.384
Служители	510
EBITDA	-10M -107M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+73.93% upside

Дивиденти
By Dow Jones
Следващи печалби	24.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	315M 2.8B
Предишно отваряне	29.29
Предишно затваряне	27.35

Настроения в новините

By Acuity

25%

75%

45 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.225 / 20.17 Подкрепа & съпротива

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.02.2026 г., 22:17 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1st Half Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16.02.2026 г., 23:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

16.02.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Decline; Prime Minister Takaichi's Policy Steps in Focus -- Market Talk

16.02.2026 г., 23:23 ч. UTC

Придобивния, сливания и поглъщания

BHP Shares Up 7.0% After Silver Streaming Deal, Profit Beat

16.02.2026 г., 23:20 ч. UTC

Придобивния, сливания и поглъщания

BHP Exploring Other Infrastructure Deals as It Chases $10 Billion Target - Interview

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Brokers Value BHP's Total Stake in Antamina Around $4.5 Billion

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Has Desalination, Other Power Assets on Which Deals Could Be Considered

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Wants to Make Sure It Does Not Give Up Any Strategic, Operational Control of Assets

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Will Allocate Cash From Asset Deals to Growth, Shareholder Returns

16.02.2026 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Won't Put Deadline on $10 Billion Cash Unlock Target

16.02.2026 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Bar Very High For Asset Deals

16.02.2026 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Sees 'Quite a Lot of Opportunities' in Potential Infrastructure Deals

16.02.2026 г., 22:35 ч. UTC

Пазарно говорене

Australian Jobs Data Could Confirm Market Too Tight -- Market Talk

16.02.2026 г., 22:02 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16.02.2026 г., 21:48 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Optimistic That Economic Backdrop Supportive For Key Commodities

16.02.2026 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals: Acquisition Immediately Increases Production and Cash Flow Profile

16.02.2026 г., 21:48 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: China's Economy Resilient; India Continues to Outperform

16.02.2026 г., 21:47 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Streaming, WAIO Power Deals Unlock Over $6 Billion of Cash Combined

16.02.2026 г., 21:47 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Sees Potential to Unlock Up to $10 Billion From Portfolio, Asset Management

16.02.2026 г., 21:47 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals to Have Combined 67.5% of All the Silver Produced From Antamina, Up From 33.75% Currently

16.02.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals: Upfront Payment to Be Funded Through Combination of Existing Liquidity and New Financing

16.02.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals Will Pay BHP Total Upfront Cash Consideration of $4.3B on Closing

16.02.2026 г., 21:46 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP Interim Dividend Represents 60% Payout Ratio

16.02.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals in Definitive Precious Metals Purchase Agreement BHP Subsidiary for Its 33.75% Portion of Silver Produced at Antamina Mine in Peru

16.02.2026 г., 21:45 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Copper Contributed 51% of 1H Underlying Ebitda

16.02.2026 г., 21:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP Net Debt $14.69 Billion at Dec. 31, Up 25% On-Year

16.02.2026 г., 21:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Net Operating Cash Flow $9.37 Billion, Up 13% On-Year

16.02.2026 г., 21:42 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Underlying Ebitda $15.46 Billion, Up 25% On-Year

16.02.2026 г., 21:42 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP Was Expected to Record Underlying Profit of $6.03 Billion According to Visible Alpha

16.02.2026 г., 21:41 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Underlying Profit $6.20 Billion, Up 22% On-Year

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

73.93% нагоре

12-месечна прогноза

Среден 48.56 USD 73.93%

Висок 80 USD

Нисък 28 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.225 / 20.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

45 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.